Efficacy of products is far from clear Marketed for the purpose of modulating cognition or a variety of affective and mental states, a growing ecosystem of neurotechnology products is being sold direct to consumers (DTC) without necessitating the physician as intermediary. Offering individuals the prospect of monitoring and manipulating a range of brain functions from memory to mental health, the major product categories are neuromonitoring devices, cognitive training applications, neurostimulation devices, and mental health apps. The market for these products is predicted to top $3 billion by 2020 (1). Yet there are good reasons to conclude that regulatory oversight of DTC neurotechnologies is insufficient. We suggest ways to provide systematic support for regulatory agencies, funding bodies, and a public that is thirsty for knowledge about the efficacy of DTC neurotechnology products.

中文翻译：

---

监督直接面向消费者的神经技术

产品的功效远未明确 以调节认知或各种情感和精神状态为目的进行营销，越来越多的神经技术产品生态系统被直接销售给消费者 (DTC)，而无需医生作为中介。为个人提供监测和操纵从记忆到心理健康的一系列大脑功能的前景，主要产品类别是神经监测设备、认知训练应用程序、神经刺激设备和心理健康应用程序。到 2020 年，这些产品的市场预计将达到 30 亿美元 (1)。然而，有充分的理由得出结论，对 DTC 神经技术的监管监督是不够的。我们建议如何为监管机构、资助机构、